



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/30 (2006.01) A61K 39/395 (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:

PCT/CN2019/105315

(22) International Filing Date:

11 September 2019 (11.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/105162

12 September 2018 (12.09.2018) CN

(71) Applicant: **EUCURE (BEIJING) BIOPHARMA CO., LTD** [CN/CN]; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).

(72) Inventors: **YANG, Yi**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **XIE, Jing-shu**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **DONG, Chunyan**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111

(CN). **YANG, Fang**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **LU, Chengyuan**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **SHEN, Yuele**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **NI, Jian**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **GUO, Yanan**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **CHEN, Yunyun**; Rm708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).

(74) Agent: **BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP)**; Room 1705, Baoyuan Building, No. 16 Qinghua East Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: This disclosure provides an anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibody, antigen-binding fragment, and the uses thereof.

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))